mTORC1 activation in childhood ependymoma and response to sirolimus
Daniel C Bowers1, Blanka Kucejova, Linda Margraf
1Department of Pediatrics, University of Texas Southwestern Medical School at Dallas, Dallas, TX 75390, USA. Daniel.Bowers@utsouthwestern.edu
Abstract:
Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient's tumor.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
